comparemela.com

Latest Breaking News On - Herthena lung01 - Page 1 : comparemela.com

Antibody-Drug Conjugates in EGFR-Mutant NSCLC

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

Evolving treatment paradigmAdvanced nonSmall cell lung cancerDrug conjugatesNon small cell lung cancerAdvanced non small cell lung cancerAdvanced nsclcNsclc treatmentEgfr mutant lung cancerEgfr mutated lung cancerSecond line treatmentHerthena lung01Tropion lung05Patritumab deruxtecanDatopotamab deruxtecan

NSCLC: Safety Outcomes from HERTHENA-Lung01

Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.

Safety outcomesNon small cell lung cancerHerthena lung01Antibody drug conjugatePatritumab deruxtecanAdverse eventsSafety profileTreatment emergent adverse events

The Role of HER3 in Non–Small Cell Lung Cancer

A medical oncologist discusses the role of HER3 in the treatment of non–small cell lung cancer and provides an overview of the HERTHENA-Lung01 clinical trial.

Small cell lungNon small cell lung cancerPatritumab deruxtecanAntibody drug conjugateHerthena lung01

Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice.

Helena yuPatritumab deruxtecanLung cancerNon small cell lung cancerEgfr mutationEgfr lung cancerEgfr tkiHerthena lung01Her3 dxdClinical trialsNovel therapyWorld conference on lung cancerWclc 20232023 wclcEfficacy dataSafety data

vimarsana © 2020. All Rights Reserved.